Basilea Pharmaceutica AG
SIX:BSLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Basilea Pharmaceutica AG
Other Long-Term Assets
Basilea Pharmaceutica AG
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Other Long-Term Assets
CHf11.7m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
106%
|
CAGR 10-Years
15%
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Other Long-Term Assets
$15.5m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
108%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Other Long-Term Assets
$32m
|
CAGR 3-Years
25%
|
CAGR 5-Years
12%
|
CAGR 10-Years
45%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Other Long-Term Assets
CHf21.6m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Other Long-Term Assets
CHf5.6m
|
CAGR 3-Years
124%
|
CAGR 5-Years
80%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Other Long-Term Assets
CHf113k
|
CAGR 3-Years
-62%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
Glance View
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
See Also
What is Basilea Pharmaceutica AG's Other Long-Term Assets?
Other Long-Term Assets
11.7m
CHF
Based on the financial report for Dec 31, 2025, Basilea Pharmaceutica AG's Other Long-Term Assets amounts to 11.7m CHF.
What is Basilea Pharmaceutica AG's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
15%
Over the last year, the Other Long-Term Assets growth was -33%. The average annual Other Long-Term Assets growth rates for Basilea Pharmaceutica AG have been -19% over the past three years , 106% over the past five years , and 15% over the past ten years .
